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Few previous studies have reported the effects of glucose-6-phosphate dehydrogenase
(G6PD)–deficiency on child health in Africa. We conducted a case-control study in which
cases (n 5 6829) were children admitted, for any reason, to Kilifi County Hospital, Kenya,
while controls (n 5 10 179) were recruited from the surrounding community. Cases were
subclassified based on their clinical and laboratory findings at admission. We calculated the
prevalence of specific diseases by G6PD c.202 genotype, the only significant cause of G6PD-
deficiency in this area, then estimated the association between genotype and admission with
specific conditions using logistic regression. Among neonates, the prevalence of jaundice
was higher in both G6PD c.202T heterozygotes (40/88; 45.5%; P 5 .004) and homo/
hemizygotes (81/134; 60.5%; P , .0001) than in wild-type homozygotes (157/526; 29.9%).
Median bilirubin levels also increased across the groups, being highest (239 mmol/L;
interquartile range 96-390 mmol/L) in G6PD c.202T homo/hemizygotes. No differences were
seen in admission hemoglobin concentrations or the prevalence of anemia or severe anemia
by G6PD c.202 genotype. On case control analysis, G6PD heterozygosity was negatively
associated with all-cause hospital admission (odds ratio 0.81; 95% confidence interval
0.73-0.90; P , .0001) and, specifically, admission with either pneumonia or Plasmodium
falciparum parasitemia; while, conversely, it was positively associated with Gram-positive
bacteremia. G6PD c.202T homo/heterozygosity was positively associated with neonatal
jaundice, severe pneumonia, the receipt of a transfusion, and in-patient death. Our study
supports the conclusion that G6PD c.202T is a balanced polymorphism in which a selective
advantage afforded to heterozygous females against malaria is counterbalanced by
increased risks of neonatal jaundice, invasive bacterial infections, and anemia.
Introduction
Glucose-6-phosphate dehydrogenase (G6PD) plays an important role in the defense against oxidant
damage, particularly in red blood cells.1 G6PD is an enzyme that is encoded by an X-linked gene (G6PD)
that is among the most polymorphic loci of humans. Approximately 200 allelic variants have been
reported to date of which some 40 have reached high frequencies in multiple populations.2 G6PD
deficiency is most common in Africa, Asia, the Mediterranean, and the Middle East, which almost
certainly reflects a survival advantage against malaria.3 G6PD deficiency is categorized by the World
Health Organization (WHO) into 4 classes according to the residual enzyme activity in hemizygous vs
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normal males.1 Clinically, the most common consequences of G6PD
deficiency are neonatal jaundice and acute hemolytic anemia,
although the frequency and severity of these complications vary
substantially depending on the degree to which enzyme activity is
impaired.2 TheG6PD c.202T allele, which results in the A-haplotype, is
the most common cause of G6PD-deficiency in Africa and affects
.30% of males in some populations.3 G6PD c.202T is a WHO
class III mutation in which hemizygotes retain ;12% of normal
G6PD activity. As a consequence, it is often considered to have a mild
phenotype, although this assumption has recently been challenged.4
Despite being so common, few epidemiological studies have been
conducted in Africa that have investigated the broad impacts of G6PD
c.202T deficiency on children’s health. In the current study, we have
investigated this question in an area where the G6PD c.202T allele
is the only significant cause of G6PD deficiency.5
Methods
Study design
First, we undertook a descriptive analysis of the clinical features and
outcome of hospital-admitted patients according to their G6PD
c.202 genotypes before then conducting a series of case-control
studies in which we investigated the association between G6PD
c.202 genotypes and admission to hospital overall and with a range
of specific diagnoses. Cases were children aged ,14 years who
were residents of the area served by the Kilifi Health and Demographic
Surveillance System in Kenya5 and who were admitted to the wards of
Kilifi County Hospital (KCH) for any reason between 1 January 2003
and 31 December 2004. Children aged 3 to 12 months who were
born within the same study area as cases between August 2006 and
September 2010, and who were recruited to a cohort study primarily
designed to study the childhood epidemiology of sickle cell disease,6
were used as controls. As such, controls were not matched to
cases but were recruited from the same catchment area. The latter
were recruits to an ongoing study, designed to investigate genetic
susceptibility to a range of childhood diseases.6 Cases were
further classified based on their clinical phenotype at the time of
admission, derived from data from a long-running surveillance
system of pediatric admissions to KCH.7 The following clinical
syndromes were included in the analysis. Neonatal conditions
were defined as admission to hospital within the first 28 days of
life. Anemia and severe anemia were defined as a hemoglobin (Hb)
level of ,110 g/L and ,80 g/L, respectively, in neonates8 and as
an Hb level of ,110 g/L and ,50 g/L beyond the neonatal period.
The latter was based on a modification of the WHO definitions9 in
which definitions for severe malaria range between ,60 g/L and
,40 g/L depending on underlying conditions and the presence
of specific clinical complications. Clinical malaria was defined as
a fever in the presence of Plasmodium falciparum parasitemia at
any density in children,1 year old or at a density of.2500 parasites
per microliter in older children, and severe malaria was defined as
malaria in association with a range of specific complications, which
included prostration, coma (cerebral malaria), respiratory distress,
an Hb level of,50 g/L (severe malaria anemia), and other syndromes
as defined by the WHO.10 Severe and very severe pneumonia were
defined using standard methods,11 whereas meningitis/encephalitis
was defined by the presence of neck stiffness, a bulging fontanelle,
prostration, or coma (defined as a Blantyre Coma Score of 3 to ,5
and ,3, respectively). Severe malnutrition was defined on the basis
of a mid-upper-arm circumference of#7.5 cm in children,6 months
of age or of#11.5 in children $6 months of age.9,12 Gastroenteritis
was defined as diarrhea ($3 loose watery stools per day) with or
without vomiting ($3 episodes per day), and jaundice was defined
clinically by its recognition by the admitting clinician. Severe anemia
was defined as an Hb level of,50 g/L irrespective of the presence
of malaria parasites. Finally, in order to identify episodes of
acute intravascular hemolysis, a specific potential complication
of G6PD deficiency, we searched both the admission and the
discharge diagnoses together with the free-text admission notes
of our electronic database for the terms “hemolysis,” “hemolytic,”
“hemoglobinuria,” “dark (urine),” “G6PD,” and “favism,” allowing
for permutations including the use of US spellings. Because of
its association with multiple health consequences and a raised
incidence of premature mortality,13 for the purpose of the current
analysis, we excluded children with sickle cell anemia (HbSS)
from both the case and the control groups.
Laboratory procedures
Hematological, biochemical, and malaria parasite data were derived
by standard methods,14 whereas blood cultures were processed in
BACTEC Peds Plus bottles using a BACTEC 9050 automated blood-
culture instrument (Becton Dickinson, UK). Positive samples were
subcultured on standard media by routine microbiological
techniques.7 Quality assurance for all laboratory tests was provided
by the UK National External Quality Assessment Service (www.
ukneqas.org.uk). Genomic DNA was extracted for genotyping from
fresh or frozen samples of whole blood using proprietary methods
(either ABI PRISM [Applied Biosystems, CA] or Qiagen DNA Blood
Mini Kit [Qiagen, West Sussex, United Kingdom]). We typed the
G6PD c.202T allele, the only significant cause of G6PD deficiency
in our study population, by amplification refractory system poly-
merase chain reaction as described in detail previously.15 All samples
were also typed for the confounder HbS as previously described.14,16
Children typing positive for HbSS were excluded from both case and
control sets for the purpose of the current analysis.
Statistical analysis
We compared the clinical, laboratory, and demographic character-
istics of children who were admitted to hospital during the study
period (cases), defined according to G6PD c.202T genotype, using
parametric or nonparametric tests as appropriate, whereas proportions
were compared using the x2 test. For the purpose of our analyses,
we categorized study participants into the 3 most physiologically
meaningful G6PD categories based on G6PD c.202T genotypes:
(i) biochemically normal individuals, girls or boys who were either
homozygous or hemizygous, respectively, for the wild-type allele at
position 202 of the G6PD gene; (ii) G6PD c.202T heterozygous
girls, who have intermediate levels of G6PD activity5; and (iii) G6PD
c.202T homozygous girls and hemizygous boys, both of whom have
G6PD deficiency. The latter group is physiologically identical with
regard to their G6PD enzyme activity, each manifesting ;12% of
normal levels.5,15 In our case-control analysis, we investigated the
association between G6PD c.202 genotype and a range of specific
diagnoses by logistic regression, adjusting for the confounders
administrative division of residence, sex, and HbS genotype. All
analyses were conducted using Stata v14.2 (StataCorp, Timberlake).
Code availability
The code associated with the statistical analysis of the primary data,
written in Stata v14.2, has been deposited on the data repository for
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the KEMRI–Wellcome Trust Research Program in Kilifi and is
available, along with appropriately anonymized data, by application
through mmunene@kemri-wellcome.org.
Ethics
Informed written consent was obtained from all study participants,
their parents, or guardians. Ethical permission for the study was




The study included 8124 children ,14 years of age who were
admitted to KCH from within the study area covered by the Kilifi
Health and Demographic Surveillance System during the 2-year
period from 1 January 2003 to 31 December 2004. Of these
potential cases, 6829 (84.1%) had samples available for analysis,
were genotyped successfully at the G6PD c.202T locus, did not
have HbSS, and were included in the current analysis (Figure 1).
The study flow for controls was as described in Uyoga et al.6 The
baseline clinical and hematological characteristics of these children,
stratified by G6PD c.202T category, are summarized in Table 1. The
groups were similar with the exceptions that G6PD c.202T–deficient
homo/hemizygotes were younger and mean cell volumes were
higher within both deficiency groups, while female heterozygotes
were significantly less stunted than G6PD c.202T wild-type
homo/hemizygotes.
G6PD deficiency among children admitted with
a range of clinical diagnoses
The clinical phenotypes and outcome of hospital-admitted neonatal
(#28 days of age) and postneonatal (.28 days of age) cases are
summarized in Tables 2 and 3, respectively. Compared with
G6PD c.202T wild-type homo/hemizygotes, the prevalence of
clinical jaundice was higher in both G6PD c.202T deficiency
groups. The prevalence was highest (60.5%) in homo/hemizygous
children admitted during the neonatal period. Although the prevalence
of jaundice was also higher in G6PD c.202T homo/hemizygous–
deficient than G6PD c.202T homozygous wild-type children admitted
during the postneonatal period, it was rare overall and was seen in only
2.4% of those who were homo/hemizygous deficient. In children with
detectable jaundice during the neonatal period, median bilirubin levels
were higher in G6PD c.202T heterozygous or homo/hemizygous
children than among wild-type homozygotes (Tables 2 and 3).
Although admission Hb levels were significantly lower among deficient
homo/hemizygotes overall, this was not true in the subgroup with
clinical jaundice, suggesting that jaundice was not related pre-
dominantly to hemolysis. Severe anemia was rare and was no more
frequent among children in the G6PD c.202 deficiency groups than
in wild-type homo/hemizygotes (Table 2). We detected only 6
occurrences in 5 individuals of terms suggestive of intravascular
hemolysis. “Dark urine” was mentioned in 4 admissions, all associated
with acute malaria, whereas “hemolysis” was mentioned during 3
admissions, 2 of which were in children with a suspected diagnosis
of sickle cell disease, although genotyping results from our current
study showed that neither were actually affected. Two episodes
were among G6PD c.202 wild-type homo/hemizygotes, whereas
1 episode was seen among each of the deficiency groups.
The independent association between sex with
a range of clinical diagnoses
Because G6PD deficiency is sex linked, we checked our data for
any independent association between sex and our specific outcomes
of interest. None were significantly associated except for one,
a significantly higher proportion of girls (325/2900; 11.2%) than
10,574 pediatric admissions 0-13
years old between 1st January 2003
and 31st December 2004  
8,124 lived within the study area
7,061 with G6PD genotypes 
2,450 lived outside the study area
1,063 no stored sample for G6PD genotyping
or genotyping unsuccessful 
6,829 cases in the case-control study
232 with sickle cell anemia (HbSS)
Figure 1. Study flow.
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boys (258/3363; 7.7%) .28 days of age were admitted with
severe malnutrition (P , .0001).
Odds ratios for G6PD c.202T genotypes among
children admitted with various conditions
The overall frequencies of G6PD deficiency genotypes among
the 6829 genotyped cases were G6PD c.202 wild-type homo/
hemizygotes, 5130 (75.1%), G6PD c.202T heterozygous girls,
809 (11.9%), and G6PD c.202T–deficient homo/hemizygotes,
890 (13.0%), whereas the comparable figures for the 10 179
controls were 7422 (72.9%), 1612 (15.8%), and 1145 (11.3%),
respectively. The odds of admission during the neonatal period
overall were lower among G6PD c.202T heterozygous females
compared with wild-type homo/hemizygotes, whereas the odds of
admission with jaundice were significantly raised (Table 4). The
odds of jaundice were further raised in G6PD c.202–deficient
homo/hemizygotes (Table 4). During the postneonatal period, the
odds of admission to hospital for any reason, or with a positive malaria
slide, or with very severe pneumonia were all lower among G6PD
c.202T heterozygous females than in wild-type homo/hemizygotes,
whereas the odds of admission with all-cause bacteremia were
raised (Table 4). The association with bacteremia varied by organism.
Although the odds for all-cause bacteremia among female hetero-
zygotes were 1.45 (95% confidence interval [CI] 1.03-2.03), this
appeared to be driven by a particular risk of Gram-positive
bacteremia, the adjusted odds ratios for Gram-positive bacteremia
being 1.34 (0.84-2.13; P 5 .22) and 1.58 (1.03-2.42; 0.038)
amongG6PD c.202T–deficient heterozygotes and homo/hemizygotes,
respectively. Although the odds for the largest group of gram-
positive organisms, S pneumoniae, were also raised (1.45; 0.78-2.69
and 1.53; 0.90-2.62, respectively), they did not reach statistical
significance (P 5 .24 and P 5 .12, respectively). We found no
significant evidence for a protective effect of G6PD c.202T–deficient
homo/hemizygosity against any syndrome individually, but it was
positively associated with admission to hospital with jaundice,
severe pneumonia, and meningitis/encephalitis and with an increased
odds of blood transfusion or death.
Discussion
We have investigated the effect of G6PD c.202T genotype on
the risk of a range of common childhood diseases in a well-
characterized population on the coast of Kenya. Based on data
from our case-control analyses, the risks of both all-cause and
malaria-positive hospital admission were significantly lower (19%
and 21%, respectively) in G6PD c.202T heterozygous girls than
in G6PD c.202T homo/hemizygous wild-type children, whereas
no impact was seen of G6PD c.202T–deficient homo/hemizygosity.
Conversely, the risk and severity of neonatal jaundice were signifi-
cantly higher in both G6PD c.202T heterozygous girls and G6PD
c.202T–deficient homo/hemizygotes, whereas the risk of gram-
positive bacteremia was raised in female heterozygotes. We
saw no evidence for an increased risk of acute intravascular
hemolysis or severe anemia among children in either of the
G6PD-deficiency groups.
G6PD deficiency is extremely common, affecting .2.5 billion
people worldwide.3 Allele frequencies of up to 32.5% are found
in some parts of sub-Saharan Africa, where G6PD c.202T is the
most important cause.3,17 Although G6PD c.202T is thought
to be asymptomatic in the majority of those affected,2 this
conclusion is based on limited epidemiological evidence, most
previous studies having been conducted in the context of specific
questions, most notably relating to favism, the risk of hemolysis
following the ingestion of specific drugs,4,18,19 or the influence of
G6PD deficiency on malaria.20,21 To the best of our knowledge, the
impact of G6PD c.202T on a wide range of child health outcomes
in Africa has not been investigated previously through a single
epidemiological study.
First, we found no evidence to suggest that severe or acute
intravascular hemolysis was a significant problem in children in
either of the G6PD c.202T deficiency groups under the epidemi-
ological circumstances that prevailed during the study period. We
saw no difference in admission Hb concentrations or in the
prevalence of severe anemia by G6PD genotype, and although
postneonatal jaundice, a potential consequence of hemolysis,






G6PD c.202T homozygous girls and
hemizygous boys P
All admissions, n (%) 5130 (75.1) 809 (11.9) n/a 890 (13.0) n/a
Median age (IQR), mo 17.2 (6.9-35.8) 16.0 (6.9-32.5) .13 14.6 (5.0-33.5) .0008
Mean WAZ (95% CI) 21.65 (21.70 to 1.62) 21.65 (21.76 to 1.55) .93 21.73 (21.83 to 1.63) .18
Mean HAZ (95% CI) 21.38 (21.42 to 1.33) 21.24 (21.35 to 1.13) .026 21.43 (21.53 to 1.33) .37
Mean Hb level (95% CI), g/L 94.3 (93.4-95.1) 91.5 (89.3-93.6) .017 93.6 (91.6-95.6) .53
Mean MCV (95% CI), fL 74.6 (74.3-75.0) 76.6 (75.7-77.5) .0001 77.7 (76.8-78.7) ,.0001
Median WBC (IQR), 3109/L 12.1 (8.8-17.0) 12.6 (8.7-17.8) .18 12.7 (9.0-17.8) .86
Median platelets (IQR), 3109/L 308 (152-464) 293 (151-459) .18 314 (180-490) .049
Median bilirubin* (IQR), mmol/L 19 (9-69) 136 (27-223) .26 110 (37-383) .48
Median parasite density† (IQR), per mL 49720 (3 599-224000) 28 399 (3 383-176400) .10 33800 (3 770-180120) .24
Percentages reflect column percentages with the exception of all admissions. P values estimated by Student t, x2, or Mann-Whitney U tests as appropriate in comparison with the G6PD
normal group.
HAZ, height-for-age Z-score; IQR, interquartile range; MCV, mean cell volume; n/a, not applicable; WAZ, weight-for-age Z-score; WBC, white blood cell count.
*Bilirubin levels among those with detectable jaundice.
†Parasite densities among the fraction with positive blood films. No independent association was seen between sex and any parameter individually.
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was significantly more common, it was only seen in a handful of
individuals. Acute hemolysis based on clinical history was also
uncommon and in most cases was attributable to malaria, although
the fact that few episodes were identified suggests that this method
was not particularly sensitive. Although G6PD c.202T deficiency
can result in severe hemolysis under specific circumstances, most
notably on exposure to high doses of strongly oxidant drugs, such
as primaquine22-24 and dapsone,4 previous reports that have not
described specific trigger factors have been extremely limited.25-27
Unfortunately, the absence of detailed data on preadmission drug
exposure does not allow us to address this issue directly in our
current study; however, the absence of a signal supports the
conclusion that acute intravascular hemolysis among children with
G6PD c.202T deficiency is rare under normal circumstances.
Our study did show, however, that in our study population G6PD
c.202 deficiency was strongly associated with neonatal jaundice,
being significantly more common in both heterozygous girls and
homo/hemizygous girls and boys than in wild-type homozygous
children. More than 40% of all the babies admitted with detectable
neonatal jaundice were either heterozygous or homo/hemizygous
for G6PD c.202. Moreover, where jaundice was present, it was
significantly more severe, median bilirubin levels being over 3 times
higher in homo/hemizygotes than in wild-type homozygotes. Although
all cases in our current study were safely managed in our well-
resourced facility, our findings suggest that both historically and in
less well-resourced facilities or in the community today, G6PD c.202
deficiency could be a significant cause of long-term neurological
damage due to neonatal hyperbilirubinemia.28 Our data support
the conclusion made by others29 that G6PD c.202 deficiency does
not cause neonatal jaundice through a mechanism that predom-
inantly involves hemolysis. Although mean Hb concentrations were
significantly lower in homo/hemizygous-deficient than in wild-type
homo/hemizygous wild-type neonates, the difference was small
(138 g/L vs 146 g/L) and the prevalence of neither anemia nor
severe anemia was significantly increased. Previous studies have
suggested that impairment of bilirubin conjugation and clearance
by the liver is etiologically more important than hemolysis.29
Unfortunately, differential bilirubin concentrations, that might have
allowed us to interrogate this question in further detail, were not
measured in our current study.
Our observation that G6PD-deficient children are at increased risk
of bacteremia, and of gram-positive bacteremia in particular, aligns
with observations from a previous study in which we investigated
the risk of S pneumoniae bacteremia in greater detail.30 In our
earlier paper, which included a larger number of bacteremic cases
recruited over a longer period of time, we found that G6PD c.202
was associated with a raised risk of S pneumoniae bacteremia via
a mechanism that was dependent on malaria, a finding that was
consistent with either an additive or a recessive model. Although we
noted that G6PD c.202 heterozygous females were significantly
more likely to be admitted with severe malnutrition, this appeared to
be explained by the significantly higher risk of severe malnutrition in
girls overall. It is unclear why this should be the case given that a sex
bias toward girls has not been commonly described in previous
studies of malnutrition. Whatever the cause, the increased risk of
malnutrition did not appear to explain the association between
heterozygosity and the risk of invasive bacterial infections given that
we found no significant relationship between sex and bacterial
infections.
The results of our current study also support those from a previous
study with regard to the protective role of G6PD deficiency against
malaria.21 In our current study, which was conducted in the same
Table 2. Distribution of clinical syndromes and outcomes among case patients admitted during the neonatal period
Syndrome
G6PD normal boys and girls
(n 5 526)
G6PD c.202T heterozygous girls
(n 5 88) P
G6PD c.202T homozygous girls and
hemizygous boys (n 5 134) P
Clinical, laboratory, and demographic features
Clinical jaundice, n (%) 157 (29.9) 40 (45.5) .004 81 (60.5) ,.0001
Bacteremia,* n (%) 34 (6.5) 9 (10.2) .20 7 (5.2) .59
Mean Hb level (95% CI), g/L 146 (143-149) 143 (136-150) .49 138 (133-143) .0086
Anemia (Hb ,110 g/L), n/N (%) 63/512 (12.3) 13/85 (15.3) .44 19/127 (15.0) .42
Severe anemia (Hb ,80 g/L), n/N (%) 14/512 (2.7) 1/85 (1.2) .40 2/127 (1.6) .45
Median bilirubin† (IQR), mmol/L 82.5 (37-191) 223 (66-319) .0001 239 (96-390) ,.0001
Mean Hb level in those with jaundice (95% CI), g/L 148 (142-153) 149 (139-159) .82 141 (134-147) .12
Median weight overall (IQR), kg 2.7 (2.1-3.2) 2.8 (2.2-3.1) .80 2.7 (2.0-3.2) .92
Median weight in those with jaundice (IQR), kg 2.7 (2.2-3.1) 2.7 (3.4-3.0) .91 2.8 (2.4-3.2) .12
Median age (IQR), d 2 (0-9) 4 (0-9) .23 4 (1-7) .60
Median age in those with jaundice (IQR), d 5 (2-8) 4.5 (3-7.5) .71 5 (3-7) .97
Outcome
Median duration of admission (IQR), d 5 (3-8) 6 (3-8.5) .08 6 (3-10) .036
Transfused, n (%) 25 (4.8) 11 (12.5) .004 28 (20.9) ,.0001
Died, n (%) 118 (22.4) 15 (17.1) .26 32 (23.9) .72
*Bacteremia was caused by the following organisms (n): Acinetobacter spp (4), Aeromonas spp (1), Enterobacter spp (8), Escherichia coli (6), Haemophilus influenzae (1), Klebsiella
pneumoniae (2), Pseudomonas aeruginosa (3), Salmonella spp (3), Staphylococcus aureus (5), b-hemolytic Streptococcus (7), Streptococcus pneumoniae (7), Vibrio cholera (3). No
independent association was seen between sex and any parameter individually.
†Plasma bilirubin levels at admission in children with visible jaundice. Denominators are shown in cases where data were missing.
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population as our previous study but within a different group of
children, we found that G6PD c.202 heterozygous girls were
significantly less likely to be admitted with a positive blood film for
malaria, whereas G6PD c.202–deficient homo/hemizygotes were
more likely to receive a blood transfusion during the course of their
admission. These observations support the conclusion that the
protective effect of G6PD c.202 heterozygosity against malaria
is balanced by an increased risk of severe anemia in G6PD
c.202–deficient homo/hemizygotes.21 Although this conclusion
supports that of some previous studies,31-34 others have suggested
that there is either no effect of G6PD deficiency on malaria risk35,36
or that protection is afforded to males and females in various
combinations.15,20,37 A key strength of ours over some of these
previous studies was its size, and therefore, the power of our
study to detect significant differences. Moreover, we used G6PD
genotyping rather than phenotyping, which is difficult to interpret in
heterozygous females because of random X-chromosome inactiva-
tion.38 Finally, our study was conducted in an area where 85% of
the variability in G6PD activity is explained by the G6PD c.202T
mutation, which alone is responsible for virtually all of the G6PD
deficiency39: allelic heterogeneity means that other G6PD variants
can have widely differing effects on G6PD activity,38 making it more
challenging to interpret studies that are conducted in areas with
multiple G6PD variants. However, our study did have some
limitations, which include the fact that it was somewhat opportu-
nistic, capitalizing on the existence of data and samples collected
for other purposes. As a result, participants were recruited over
a 2-year period during which the transmission of malaria and other
diseases varied.40 Second, although our control participants were
recruited from the same area as cases, they were younger and were
recruited several years later than the cases, meaning that we could
not correct for age. However, we believe that this would be more
likely to result in negative rather than positive confounding because
any positive selection for G6PD-deficiency alleles by malaria would
result in a rising prevalence by age and over time, which would have
the effect of enhancing rather than reducing the differences that we
have observed.
Although there was some degree of overlap between the cases
included in the current study and cases recruited to two of our
previously published studies, both of the earlier studies were
conducted with the aim of investigating the relationship between
G6PD deficiency and specific conditions and the degree of that
overlap was small. Our previous paper on severe malaria21 included
2220 cases admitted between 1995 and 2008, whereas that on
pneumococcal bacteremia involved 429 cases admitted between
1998 and 2010.30 In the current study, we included all children
(cases 5 6829) who were recruited, for any reason, during the
2-year period between January 2003 and December 2004,
a sample that included 483 children (7% of cases in the current
study) who presented with either severe malaria or pneumococcal
bacteremia and therefore were also included as cases in the
previous studies. Although the restricted recruitment period in
our current study means that it is less well powered to investigate
Table 3. Distribution of clinical syndromes and outcomes among post-neonatal case patients
Syndrome
G6PD normal boys and girls
(n 5 4604)
G6PD c.202T heterozygous girls
(n 5 721) P
G6PD c.202T homozygous girls and
hemizygous boys (n 5 756) P
Clinical syndromes,* n (%)
Malaria 1422 (30.9) 231 (32.0) .53 228 (30.2) .69
Severe malaria 280 (6.1) 53 (7.4) .19 36 (4.8) .15
Severe pneumonia 96 (2.1) 15 (2.1) .99 26 (3.4) .021
Very severe pneumonia 2593 (56.3) 406 (56.3) .99 427 (56.5) .93
Meningitis/encephalitis 843 (18.3) 147 (20.4) .18 137 (18.1) .90
Severe malnutrition 408 (8.9) 104 (14.4) ,.0001 54 (7.1) .20
Gastroenteritis 1161 (25.2) 173 (24.0) .48 193 (25.5) .86
Jaundice 49 (1.1) 9 (1.3) .66 18 (2.4) .003
Other 550 (12.0) 72 (10.0) .12 79 (8.9) .097
Laboratory-based syndromes
Bacteremia,† n (%) 201 (4.4) 46 (6.4) .017 38 (5.0) .41
Severe anemia, n (%) 333 (7.2) 62 (8.6) .19 59 (7.8) .58
Mean Hb level in children with jaundice (95% CI), g/L 72.7 (63.5-81.9) 79.4 (67.9-91.0) .54 84.6 (74.2-94.9) .15
Malaria blood film positive, n (%) 1793 (38.9) 298 (41.3) .22 281 (37.2) .35
Outcome
Median duration of admission (IQR), d 3 (2-5) 3 (2-5) .30 3 (2-5) .33
Transfused, n (%) 340 (7.4) 55 (7.6) .87 67 (8.9) .16
Died, n (%) 201 (4.4) 35 (4.9) .55 35 (4.6) .74
*Some children displayed .1 clinical feature and therefore appear more than once.
†Bacteremia was caused by the following organisms (n): Acinetobacter spp (32), Enterobacter spp (1), Escherichia coli (23), Haemophilus influenzae (18), Klebsiella spp (8), Neisseria
spp (2), Proteus mirabilis (1), Pseudomonas aeruginosa (6), other Pseudomonas spp (5), Salmonella spp (30), Serratia spp (1), Staphylococcus aureus (21), b-hemolytic Streptococcus
(30), S pneumoniae (107). No independent association was seen between sex and any parameter individually with the exception of severe malnutrition, which was significantly more common
in girls overall (see text).
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associations between G6PD deficiency and those 2 specific
diagnoses, that was not our aim. Our current study was broadly
hypothesis free and was aimed at identifying within which of
many clinical phenotypic groups the G6PD-deficient children
were to be found. A second issue of potential concern is the
fact that, although collected from the same geographic area, for
practical and pragmatic reasons the controls for our study were
recruited during a different time period from cases and, unlike
cases, included only children ,1 year old. This would be a major
issue if the population structure with regard to G6PD-deficiency
alleles changed significantly within a single generation; however,
current levels of mortality within the study population (recently
estimated at 2.4 [2.0-2.8]/1000 person-years in the postneona-
tal period among children without sickle cell disease6) coupled
with the degree to which G6PD deficiency is likely to affect
mortality, make it highly unlikely that this design would result in
significant bias.
In summary, in a large observational and case-control study
conducted in Kenya, we have shown that although G6PD c.202
deficiency is not associated with a major risk of severe intravascular
hemolysis, it is responsible for almost half of all cases of neonatal
jaundice. We conclude that the G6PD c.202 allele is under
balancing selection in Africa, positive selection by malaria for
heterozygous females being counterbalanced by an increased
risk of neonatal jaundice and gram-positive bacteremia in both
deficiency groups and by an increased risk of anemia among
homo/hemizygotes.
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